TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) is now available.
CK Life Sciences International (Holdings), Inc. announced a transaction involving the sale of 100% membership interests in a subsidiary to a purchaser for US$125 million, with additional milestone payments up to US$95 million. The transaction aims to combine the businesses of Polynoma and the purchaser, enhancing their therapeutic pipeline with complementary cancer treatments and leveraging the purchaser’s Nasdaq listing to promote and fundraise for the development of seviprotimut-L, a melanoma vaccine.
The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates in the biotechnology industry, focusing on the development of therapeutic candidates for cancer treatment. The company is involved in creating innovative solutions to address significant unmet needs in oncology, with a market focus on cancer vaccines and treatments for metastatic cancer.
Average Trading Volume: 7,743,813
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.8B
See more data about 0775 stock on TipRanks’ Stock Analysis page.